Needham analyst Chad Messer maintained a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) on Friday, setting a price target of $166, which is approximately 100.00% above the present share price of $83.
Messer expects Sarepta Therapeutics to post earnings per share (EPS) of -$2.41 for the first quarter of 2021.
The current consensus among 19 TipRanks analysts is for a Moderate Buy rating of shares in Sarepta Therapeutics, with an average price target of $127.
The analysts price targets range from a high of $207 to a low of $72.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $145.14 million and a net profit of -$170.72 million. The company's market cap is $6.59 billion.
According to TipRanks.com, Needham analyst Chad Messer is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.4% and a 48.95% success rate.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.